Meng-Fen Wu

Meng-Fen Wu

Auto-generated profile, based on publicly available information

Meng-Fen Wu

Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, Texas

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
TPThomas Pfeiffer
Thomas Pfeiffer
ITIfigeneia Tzannou
Ifigeneia Tzannou
MWMengfen Wu
Mengfen Wu
CRCarlos Ramos
Carlos Ramos
GSGhadir Sasa
Ghadir Sasa
BOBilal Omer
Bilal Omer
Purpose: Viral infections are a major cause of morbidity and mortality following allogeneic hematopoietic cell transplantation (allo-HCT). In the absence of safe and effective antiviral treatments, virus-specific T cells have emerged as a promising therapeutic option. Posoleucel is a multivirus-specific T-cell therapy for off-the-shelf use against six viral infections that commonly occur in allo-HCT recipients: adenovirus, BK virus (BKV), cytomegalovirus, Epstein–Barr virus, human herpes virus-6, and JC virus. Patients and Methods: We conducted an open-label, phase II trial to determine the feasibility and safety of posoleucel in allo-HCT recipients infected with one or more of these viruses. Infections were either unresponsive to or patients were unable to tolerate standard antiviral therapies. Fifty-eight adult and pediatric patients were enrolled and treated. Results: Posoleucel was well tolerated, with no cytokine release syndrome or other infusion-related toxicities; two patients (3.4%) developed Grade 2 and one patient (1.7%) Grade 3 GvHD during the trial. The overall response rate 6 weeks after the first posoleucel infusion was 95%, with a median plasma viral load reduction of 97%. Of the 12 patients who had two or more target viral infections identified at study entry, 10 (83%) had a clinical response for all evaluable viruses. Of the 23 patients treated for refractory BKV-associated hemorrhagic cystitis, 74% had resolution of symptoms and macroscopic hematuria by 6 weeks post-infusion. Conclusions: In this open-label trial, treatment of refractory viral infections/disease in allo-HCT recipients with posoleucel was feasible, safe, and effective.

30 March 2023
Verified
Other
Open access
VIVandana Iyer
Vandana Iyer
IKIna Klebba
Ina Klebba
JMJessica McCready
Jessica McCready
LALisa Arendt
Lisa Arendt
MBMonica Betancur-Boissel
Monica Betancur-Boissel
CKCharlotte Kuperwasser
Charlotte Kuperwasser

30 March 2023
Verified
Other
Open access
VIVandana Iyer
Vandana Iyer
IKIna Klebba
Ina Klebba
JMJessica McCready
Jessica McCready
LALisa Arendt
Lisa Arendt
MBMonica Betancur-Boissel
Monica Betancur-Boissel
CKCharlotte Kuperwasser
Charlotte Kuperwasser